Oppenheimer Holdings Inc. set a $43.00 target price on Teva Pharmaceutical Industries Ltd (NYSE:TEVA) in a report published on Thursday morning. The firm currently has a buy rating on the stock.

Several other research firms have also issued reports on TEVA. BTIG Research reiterated a neutral rating on shares of Teva Pharmaceutical Industries in a report on Thursday, April 6th. Royal Bank of Canada reiterated an outperform rating and set a $42.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 14th. Citigroup Inc reiterated a buy rating and set a $47.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 7th. Vetr lowered shares of Teva Pharmaceutical Industries from a strong-buy rating to a buy rating and set a $40.48 target price for the company. in a report on Thursday, February 16th. Finally, Maxim Group lowered shares of Teva Pharmaceutical Industries from a buy rating to a hold rating and lowered their target price for the company from $49.00 to $41.00 in a report on Friday, January 6th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $45.14.

Teva Pharmaceutical Industries (NYSE:TEVA) traded up 1.20% during midday trading on Thursday, hitting $31.13. The company’s stock had a trading volume of 6,457,434 shares. The stock has a 50 day moving average of $32.75 and a 200 day moving average of $36.56. The company has a market cap of $31.60 billion, a PE ratio of 444.71 and a beta of 0.58. Teva Pharmaceutical Industries has a 52-week low of $30.57 and a 52-week high of $57.52. Teva Pharmaceutical Industries also was the target of some unusual options trading on Thursday. Traders acquired 422 put options on the stock. This is an increase of 111% compared to the average volume of 200 put options.



Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Monday, February 13th. The company reported $1.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.02. The business had revenue of $6.25 billion for the quarter, compared to analysts’ expectations of $6.26 billion. Teva Pharmaceutical Industries had a return on equity of 17.46% and a net margin of 1.50%. The business’s revenue was up 33.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.32 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries will post $4.82 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Oppenheimer Holdings Inc. Reiterates “$43.00” Price Target for Teva Pharmaceutical Industries Ltd (TEVA)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/04/21/teva-pharmaceutical-industries-ltd-teva-given-a-43-00-price-target-by-oppenheimer-holdings-inc-analysts-updated.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. increased its position in Teva Pharmaceutical Industries by 20.9% in the fourth quarter. Franklin Resources Inc. now owns 56,635,303 shares of the company’s stock valued at $2,052,926,000 after buying an additional 9,775,505 shares during the period. Barrow Hanley Mewhinney & Strauss LLC increased its position in Teva Pharmaceutical Industries by 22.1% in the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 32,455,432 shares of the company’s stock valued at $1,176,510,000 after buying an additional 5,884,444 shares during the period. Capital Research Global Investors increased its position in Teva Pharmaceutical Industries by 20.9% in the third quarter. Capital Research Global Investors now owns 20,875,749 shares of the company’s stock valued at $960,493,000 after buying an additional 3,609,949 shares during the period. Highfields Capital Management LP boosted its stake in shares of Teva Pharmaceutical Industries by 106.2% in the fourth quarter. Highfields Capital Management LP now owns 16,867,447 shares of the company’s stock valued at $611,445,000 after buying an additional 8,686,905 shares in the last quarter. Finally, Paulson & CO. Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $577,310,000. 55.03% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related stocks with our FREE daily email newsletter.